These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 8246137)

  • 1. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
    Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R
    J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs.
    Damiano BP; Giardino EC; Haertlein BJ; Stump GL; Mitchell JA; Falotico R
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):300-10. PubMed ID: 7511761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Y-27152, a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state.
    Nakajima T; Shinohara T; Yaoka O; Fukunari A; Shinagawa K; Aoki K; Katoh A; Yamanaka T; Setoguchi M; Tahara T
    J Pharmacol Exp Ther; 1992 May; 261(2):730-6. PubMed ID: 1578381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive and haemodynamic properties of the potassium channel activating (-) enantiomer of cromakalim in animal models.
    Clapham JC; Hamilton TC; Longman SD; Buckingham RE; Campbell CA; Ilsley GL; Gout B
    Arzneimittelforschung; 1991 Apr; 41(4):385-91. PubMed ID: 1907150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system.
    Cavero I; Pratz J; Mondot S
    Z Kardiol; 1991; 80 Suppl 7():35-41. PubMed ID: 1838848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries.
    Nielsen-Kudsk JE
    Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular activities of the new potent and long-lasting antihypertensive calcium entry blocker (+-)-3-ethyl,5-methyl,2- ([2-(formylamino)-ethyl]- thiomethyl)-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicar box ylate.
    Germini M; Passoni A; Casciarri I; Bosetti P; Piazzoni L; Cazzulani P; Gandolfi CA; Tofanetti O; Ceserani R
    Arzneimittelforschung; 1992 Jan; 42(1):1-8. PubMed ID: 1586373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo cardiac electrophysiologic effects of RWJ 29009, a new potassium-channel activator, in comparison to cromakalim and nicardipine.
    Damiano BP; Stump GL; Cheung WM; Salata JJ
    J Cardiovasc Pharmacol; 1993 Jul; 22(1):143-52. PubMed ID: 7690086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic profiles of YM934, a novel potassium channel opener.
    Uchida W; Masuda N; Taguchi T; Shibasaki K; Shirai Y; Asano M; Matsumoto Y; Tsuzuki R; Fujikura T; Takenaka T
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):180-7. PubMed ID: 7511745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible involvement of ATP-dependent K-channel related mechanisms in the antihypertensive and cough suppressant effects of the novel ACE inhibitor (2S, 3aS, 7aS)-1-(N2-nicotinoyl-L-lysyl-gamma-D-glutamyl)octahydro-1H- indole-2-carboxylic acid.
    Nagata S; Takeyama K; Hosoki K; Karasawa T
    Arzneimittelforschung; 1997 Jun; 47(6):726-30. PubMed ID: 9239450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K(+)-channel activators in vascular smooth muscle.
    Cox RH
    Prog Clin Biol Res; 1990; 334():171-85. PubMed ID: 2309006
    [No Abstract]   [Full Text] [Related]  

  • 12. Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels.
    Cavero I; Mondot S; Mestre M
    J Pharmacol Exp Ther; 1989 Mar; 248(3):1261-8. PubMed ID: 2495353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased vasodilator responsiveness to BRL 34915 in spontaneously hypertensive versus normotensive rats: contrast with nifedipine.
    Falotico R; Keiser J; Haertlein B; Cheung WM; Tobia A
    Proc Soc Exp Biol Med; 1989 Feb; 190(2):179-85. PubMed ID: 2915996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of nilvadipine on the cardiovascular system in experimental animals.
    Ohtsuka M; Koibuchi Y; Sakai S; Tsujioka K; Fujiwara T; Ozaki T; Maeda K; Motoyama I; Horiai H; Ono T
    Arzneimittelforschung; 1988 Nov; 38(11):1605-18. PubMed ID: 3214444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RP 49356 and cromakalim relax airway smooth muscle in vitro by opening a sulphonylurea-sensitive K+ channel: a comparison with nifedipine.
    Raeburn D; Brown TJ
    J Pharmacol Exp Ther; 1991 Feb; 256(2):480-5. PubMed ID: 1899701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rat peritoneal neutrophils selectively relax vascular smooth muscle.
    Rimele TJ; Armstrong SJ; Grimes D; Sturm RJ
    J Pharmacol Exp Ther; 1991 Sep; 258(3):963-71. PubMed ID: 1679853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive effects of the novel potassium channel activator SKP-450 and its major metabolites in rats.
    Shin HS; Seo HW; Oh JH; Lee BH
    Arzneimittelforschung; 1998 Oct; 48(10):969-78. PubMed ID: 9825113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rubidium on responses to potassium channel openers in rat isolated aorta.
    Greenwood IA; Weston AH
    Br J Pharmacol; 1993 Aug; 109(4):925-32. PubMed ID: 8401946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil.
    Longman SD; Clapham JC; Wilson C; Hamilton TC
    J Cardiovasc Pharmacol; 1988; 12(5):535-42. PubMed ID: 2468052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lacidipine: a calcium antagonist with potent and long-lasting antihypertensive effects in animal studies.
    Micheli D; Collodel A; Semeraro C; Gaviraghi G; Carpi C
    J Cardiovasc Pharmacol; 1990 Apr; 15(4):666-75. PubMed ID: 1691398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.